By

Jeff Berkowitz

15
Apr
2020

Don’t Waste this Crisis: Solving the Patient Cost-Share Problem

Much attention in this pandemic has been focused on life sciences – the companies developing new therapies, vaccines, and diagnostics.  But insurers have also begun to play a role. All of the top private payers — UnitedHealthcare, Cigna, Aetna, Anthem, and Humana — have expanded access to, and cut patient costs of, telehealth services; eliminated patient cost-sharing for COVID-19-related diagnosis...
Read More
26
Mar
2020

Pharmacy as the Biomarker of Biopharma’s Strategic Change, After Coronavirus

Maybe it was my jarring transition from a decade and a half inside the gilded halls of large pharma to the rough-and-tumble world of retail pharmacy 10 years ago, but I’m a wee bit cautious of the current self-congratulatory tone of the biopharma industry’s response to the pandemic.  I’ll certainly be delighted if Regeneron and Sanofi’s IL-6 receptor inhibitor sarilumab...
Read More